Alan Tan, MD

Associate Professor of Medicine, Division of Hematology Oncology at Vanderbilt University Medical Center

Articles by Alan Tan, MD

Alan Tan, MDCRPC | March 5, 2025
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
View More
Alan H. Bryce, MDProstate Cancer | February 27, 2025
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
Alan H. Bryce, MDProstate Cancer | February 27, 2025
The panel discusses data from PEACE-3 and maintaining ARSI therapy with emerging combination treatments.
Alan H. Bryce, MDProstate Cancer | February 27, 2025
The experts discuss treatment selection in mHSPC and share insights from STOPCAP and ARANOTE on ARSI use in older patients.
Alan H. Bryce, MDProstate Cancer | February 27, 2025
The panel covers metastasis-directed therapy and trials including SWOG 1802 in oligometastatic prostate cancer.
Alan H. Bryce, MDProstate Cancer | February 27, 2025
The panelists examine biomarker adoption challenges and the impact of PSMA PET on staging and treatment decisions.
Alan Tan, MDProstate Cancer | February 27, 2025
Experts discuss advances in biomarker testing, treatment intensification, and the impact of TALAPRO-2 in prostate cancer care
David Morris, MD, FACSmHSPC | December 12, 2024
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
David Morris, MD, FACSmHSPC | December 12, 2024
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
David Morris, MD, FACSmHSPC | December 12, 2024
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
David Morris, MD, FACSCRPC | December 12, 2024
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
David Morris, MD, FACSmHSPC | December 12, 2024
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
David Morris, MD, FACSCRPC | December 12, 2024
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | October 22, 2024
In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | October 22, 2024
In the fifth segment of this roundtable, the panelists discuss the challenges and barriers of ipi-nivo therapy.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | October 22, 2024
The fourth segment of this roundtable series focuses on the potential benefits of subcutaneous nivolumab versus IV nivolumab.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | December 30, 2024
The third segment of this roundtable focuses on key treatment endpoints when deciding between IO-IO and IO-TKI regimens.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | December 30, 2024
The panel delves into the utility of sarcomatoid features, PD-L1 status, and emerging biomarkers like KIM 1 and ctDNA.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | December 30, 2024
An expert panel debates the latest strategies for optimizing first-line treatment for advanced renal cell carcinoma.
Brad McGregor, MDRenal Cell Carcinoma | June 3, 2024
The panel shared their excitement for the road ahead in kidney cancer.